Loading clinical trials...

QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT) | Clinical Trials | Clareo Health

COMPLETED

QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)

Monitoring QT Intervals Using LINQ/LINQII in Patients Undergoing Antiarrhythmic Drug Loading

NCT05488470•Medtronic Cardiac Rhythm and Heart Failure

Summary

The LINQ QT Study is a prospective, non-randomized, multi-center, observational, post-market clinical study investigating QT interval changes due to antiarrhythmic drug loading.

Detailed Description

The purpose of this study is to determine if QT interval changes are detected during and after antiarrhythmic drug loading by the designed QT detection algorithm from LINQ ECG. The QT intervals during the anti arrhythmic loading hospitalization period will be compared for all patients to analyze QT changes that may be caused due to antiarrhythmic drugs.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients implanted with LINQ/LINQII prior to the study enrollment (no more than 50% patients implanted with LINQII), but no greater than 2.5 years for LINQ or 3.5 years for LINQII, or patients who are indicated to receive a LINQ/LINQII implant at least 7 days prior to antiarrhythmic drug loading
•Patients who are scheduled to receive antiarrhythmic drug loading
•Age 18-80
•Patient is willing and able to comply with the protocol, including follow-up visits, and performing Holter recordings and patient activation transmissions

Exclusion Criteria

•Patients who have a contraindication to long-term antiarrhythmic therapy
•Patients not suitable for long-term antiarrhythmic therapy
•Patients with a previous, existing cardiac implantation (i.e., cardiac pacemaker or cardiac resynchronization requiring \> 40% pacing, implantable cardioverter defibrillator (ICDs))
•Patients with permanent and persistent AF
•Co-enrollment in another study or planning to participate in a concurrent device study during the course of this clinical study that could confound the results

Locations (3)

Baptist Hospital

Jacksonville, Florida, United States

OhioHealth Research and Innovation Institute (OHRI)

Columbus, Ohio, United States

Bay Area Hospital

Coos Bay, Oregon, United States

Key Dates

Start Date

February 20, 2023

Primary Completion Date

June 10, 2024

Completion Date

July 23, 2024

Last Updated

May 13, 2025

Enrollment

ACTUAL participants

Conditions

Atrial ArrhythmiaQT Interval, Variation inArrhythmias, Cardiac

Interventions

LINQ/LINQ II

DEVICE

Hybrid Ablation of Atrial Fibrillation in Heart Failure

NCT05411614

Persistent Atrial FibrillationAtrial Fibrillation, Persistent+4 more

View study

RECRUITINGNA

VOLT CE Mark Study

NCT06106594

Atrial ArrhythmiaAtrial Fibrillation+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 13, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)

Inclusion Criteria

Exclusion Criteria

Hybrid Ablation of Atrial Fibrillation in Heart Failure

VOLT CE Mark Study

Testing VIRTUES Patient Care Sets in Cardiac Patients (VIRTUES Cardiac Care)

Biospecimen Repository for Cardiac Arrhythmias at the Cleveland Clinic

The Leadless AV Versus DDD Pacing Study

Acute Kidney Injury Genomics and Biomarkers in TAVR Study